MX2021002590A - Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. - Google Patents

Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.

Info

Publication number
MX2021002590A
MX2021002590A MX2021002590A MX2021002590A MX2021002590A MX 2021002590 A MX2021002590 A MX 2021002590A MX 2021002590 A MX2021002590 A MX 2021002590A MX 2021002590 A MX2021002590 A MX 2021002590A MX 2021002590 A MX2021002590 A MX 2021002590A
Authority
MX
Mexico
Prior art keywords
methods
pain
treat pain
compound
phenoxypropylamine compound
Prior art date
Application number
MX2021002590A
Other languages
English (en)
Spanish (es)
Inventor
Nadine Noel
Jay Saoud
Remy Luthringer
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of MX2021002590A publication Critical patent/MX2021002590A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021002590A 2018-09-04 2019-09-04 Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. MX2021002590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726800P 2018-09-04 2018-09-04
PCT/US2019/049492 WO2020101790A2 (en) 2018-09-04 2019-09-04 Methods of using a phenoxypropylamine compound to treat pain

Publications (1)

Publication Number Publication Date
MX2021002590A true MX2021002590A (es) 2021-05-31

Family

ID=69641874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002590A MX2021002590A (es) 2018-09-04 2019-09-04 Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.

Country Status (15)

Country Link
US (2) US11766430B2 (https=)
EP (1) EP3846812A2 (https=)
JP (2) JP7439096B2 (https=)
KR (1) KR102886521B1 (https=)
CN (1) CN112955145A (https=)
AU (2) AU2019381269B2 (https=)
BR (1) BR112021004030A2 (https=)
CA (1) CA3110652A1 (https=)
CL (1) CL2021000531A1 (https=)
GB (1) GB2591937B (https=)
IL (1) IL281166B2 (https=)
MA (1) MA53565A (https=)
MX (1) MX2021002590A (https=)
UA (1) UA129837C2 (https=)
WO (1) WO2020101790A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
JP2024520463A (ja) 2021-05-24 2024-05-24 メディコン ファーマシューティカルズ,インコーポレイテッド 化学療法誘発性末梢神経障害に関連する疼痛の処置
EP4272826A3 (en) * 2021-05-24 2024-01-17 Medicon Pharmaceuticals, Inc. Treating pain associated with diabetic peripheral neuropathy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207343A (en) 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2244438T3 (es) * 1999-05-24 2005-12-16 Mitsubishi Pharma Corporation Compuestos de fenoxipropilamina.
ES2220582T3 (es) 1999-12-20 2004-12-16 Eli Lilly And Company Derivados de piperidina y su uso como antagonistas de receptor de serotonina.
ATE409475T1 (de) * 2001-02-20 2008-10-15 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
DK1423168T3 (da) * 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
SA08280759B1 (ar) 2007-01-10 2011-05-04 سولفاي فارماسوتيكالز بي . في مركبات من عوامل مضادة لشبيه القنب – cb1 ومكونات هيكلية من مثبطات إعادة إمتصاص السيروتونين بأندلابين أو فلوكسامين
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
RU2424799C1 (ru) 2010-03-29 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ коррекции депрессивных расстройств производными тиетан-1,1-диоксида в эксперименте
DK2948143T3 (da) 2013-01-24 2021-07-26 Minerva Neurosciences Inc Anvendelse af phenoxypropylaminforbindelser til behandling af depression
WO2017205399A1 (en) * 2016-05-25 2017-11-30 Minerva Neurosciences, Inc. (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Also Published As

Publication number Publication date
US11766430B2 (en) 2023-09-26
IL281166A (en) 2021-04-29
KR102886521B1 (ko) 2025-11-17
WO2020101790A3 (en) 2020-07-09
UA129837C2 (uk) 2025-08-20
US20200069672A1 (en) 2020-03-05
IL281166B1 (en) 2025-04-01
AU2025204043A1 (en) 2025-06-19
JP2024056875A (ja) 2024-04-23
WO2020101790A2 (en) 2020-05-22
GB2591937B (en) 2023-06-07
EP3846812A2 (en) 2021-07-14
US20240016790A1 (en) 2024-01-18
JP7439096B2 (ja) 2024-02-27
CA3110652A1 (en) 2020-05-22
GB202104738D0 (en) 2021-05-19
AU2019381269B2 (en) 2025-03-06
IL281166B2 (en) 2025-08-01
KR20210061357A (ko) 2021-05-27
BR112021004030A2 (pt) 2021-06-22
AU2019381269A1 (en) 2021-03-18
MA53565A (fr) 2021-07-14
CN112955145A (zh) 2021-06-11
GB2591937A (en) 2021-08-11
CL2021000531A1 (es) 2021-10-08
JP2021536506A (ja) 2021-12-27

Similar Documents

Publication Publication Date Title
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2023010063A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EA202193276A1 (ru) Способы лечения холангиокарциномы